scispace - formally typeset
S

Sam S. Chang

Researcher at Veterans Health Administration

Publications -  21
Citations -  2909

Sam S. Chang is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Bladder cancer & Cystectomy. The author has an hindex of 13, co-authored 21 publications receiving 2514 citations. Previous affiliations of Sam S. Chang include University of Alabama at Birmingham & University of Oklahoma.

Papers
More filters
Journal ArticleDOI

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

TL;DR: The intensity and scope of care for NMIBC should focus on patient, disease, and treatment response characteristics, and a risk-stratified approach categorizes patients into broad groups of low-, intermediate-, and high-risk.
Journal ArticleDOI

Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update

TL;DR: The AUA’s PGC elected to update the initial report by appointing a panel to develop a new guideline for the management of nonmuscle invasive bladder cancer founded on evidence-based outcomes in the literature as well as expert opinion.
Patent

Remote monitoring, configuring, programming and diagnostic system and method for vehicles and vehicle components

TL;DR: In this article, a system and method for monitoring, configuring, programming and/or diagnosing operation of at least one vehicle includes an on-board unit disposed on the vehicle to send and receive data corresponding to vehicle operating characteristics.
Journal ArticleDOI

Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline

TL;DR: Evaluation for patients on active surveillance and following definitive therapy for renal neoplasms should include physical examination, renal function, serum studies and imaging and should be tailored according to recurrence risk, comorbidities and monitoring for treatment sequelae.

Original Articles DELAYING RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER RESULTS IN WORSE PATHOLOGICAL STAGE

TL;DR: In this article, the authors determined whether the interval between diagnosis of muscle invasion and definitive radical cystectomy influenced pathological staging outcome and found that those patients with an interval greater than 90 days were more likely to have pT3 or higher, non-organ confined disease compared to those patients undergoing cystect before 90 days (81% versus 52%, p 0.01).